$BBIO
BridgeBio Pharma, Inc. Stock $bbio

$bbio Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000095017024018811 Filed on February 22, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$211.1M	$1.745M	$9.303M
YoY Change	11461.88%	-6.68%	-88.02%
Cost Of Revenue	$598.0K	$598.0K	$2.446M
YoY Change	-8.14%	-7.57%	-28.77%
Gross Profit	$210.5M	$1.147M	$6.857M
YoY Change	17816.77%	-6.21%	-90.76%
Gross Profit Margin	99.72%	65.73%	73.71%
Selling, General & Admin	$65.81M	$47.58M	$150.6M
YoY Change	111.54%	49.34%	5.17%
% of Gross Profit	31.26%	4148.47%	2196.15%
Research & Development	$141.6M	$130.8M	$455.7M
YoY Change	52.45%	43.92%	14.08%
% of Gross Profit	67.25%	11405.75%	6645.92%
Depreciation & Amortization	$1.596M	$1.584M	$6.494M
YoY Change	-2.27%	-4.58%	-4.09%
% of Gross Profit	0.76%	138.1%	94.71%
Operating Expenses	$207.4M	$178.4M	$606.3M
YoY Change	67.28%	45.33%	11.73%
Operating Profit	$343.0K	-$177.3M	-$607.4M
YoY Change	-100.27%	45.84%	18.58%
Interest Expense	-$19.40M	-$14.69M	$81.29M
YoY Change	-196.4%	-7.6%	1.06%
% of Operating Profit	-5654.81%
Other Income/Expense, Net	$9.483M	$21.78M	-$45.88M
YoY Change	-157.23%	377.59%	-266.54%
Pretax Income	-$36.16M	-$170.3M	-$565.8M
YoY Change	-74.67%	21.17%	16.65%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$35.22M	-$168.1M	-$653.3M
YoY Change	-75.33%	22.21%	34.79%
Net Earnings / Revenue	-16.68%	-9635.99%	-7021.94%
Basic Earnings Per Share	-$0.20		-$3.95
Diluted Earnings Per Share	-$0.20	-$0.96	-$3.95
COMMON SHARES
Basic Shares Outstanding	175.8M	174.0M	162.8M
Diluted Shares Outstanding	178.7M		162.8M

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$519.7M	$375.9M	$375.9M
YoY Change	5.78%	-20.34%	-20.34%
Cash & Equivalents	$519.7M	$375.9M	$375.9M
Short-Term Investments	$44.47M	$58.95M	$58.95M
Other Short-Term Assets	$263.7M	$42.71M	$42.71M
YoY Change	329.47%	-44.48%	-44.48%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$783.4M	$477.6M	$418.6M
YoY Change	41.74%	-12.98%	-23.72%
LONG-TERM ASSETS
Property, Plant & Equipment	$19.47M	$11.82M	$19.84M
YoY Change	43.49%	-18.9%	-21.4%
Goodwill
YoY Change
Intangibles	$25.72M	$26.32M
YoY Change	-8.51%	-8.33%
Long-Term Investments	$0.00	$58.95M	$58.95M
YoY Change
Other Assets	$20.72M	$22.63M	$22.63M
YoY Change	-0.22%	11.87%	11.87%
Total Long-Term Assets	$65.91M	$68.79M	$127.7M
YoY Change	-9.69%	-7.27%	72.19%
TOTAL ASSETS
Total Short-Term Assets	$783.4M	$477.6M	$418.6M
Total Long-Term Assets	$65.91M	$68.79M	$127.7M
Total Assets	$849.3M	$546.4M	$546.4M
YoY Change	35.75%	-12.3%	-12.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$4.728M	$10.66M	$10.66M
YoY Change	16.0%	-7.81%	-7.81%
Accrued Expenses	$118.2M	$129.1M	$129.1M
YoY Change	37.75%	26.89%	26.89%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$123.0M	$143.8M	$139.7M
YoY Change	27.31%	18.46%	15.06%
LONG-TERM LIABILITIES
Long-Term Debt	$1.716B	$446.4M	$1.727B
YoY Change	293.78%	3.59%	1.12%
Other Long-Term Liabilities	$47.28M	$9.361M	$22.47M
YoY Change	170.17%	-64.87%	-42.26%
Total Long-Term Liabilities	$1.763B	$455.8M	$1.749B
YoY Change	289.0%	-0.4%	0.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$123.0M	$143.8M	$139.7M
Total Long-Term Liabilities	$1.763B	$455.8M	$1.749B
Total Liabilities	$1.899B	$1.889B	$1.901B
YoY Change	3.24%	1.12%	1.22%
SHAREHOLDERS EQUITY
Retained Earnings	-$2.596B	-$2.561B
YoY Change	26.16%	33.49%
Common Stock	$1.821B	$1.481B
YoY Change	64.54%	57.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$275.0M	$275.0M
YoY Change	0.0%	0.0%
Treasury Stock Shares
Shareholders Equity	-$1.050B	-$1.354B	-$1.354B
YoY Change
Total Liabilities & Shareholders Equity	$849.3M	$546.4M	$546.4M
YoY Change	35.75%	-12.3%	-12.3%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$35.22M	-$168.1M	-$653.3M
YoY Change	-75.33%	22.21%	34.79%
Depreciation, Depletion And Amortization	$1.596M	$1.584M	$6.494M
YoY Change	-2.27%	-4.58%	-4.09%
Cash From Operating Activities	-$219.5M	-$124.8M	-$527.7M
YoY Change	52.12%	33.87%	25.8%
INVESTING ACTIVITIES
Capital Expenditures	$1.492M	$436.0K	$1.306M
YoY Change	12333.33%	-45.57%	-72.91%
Acquisitions
YoY Change
Other Investing Activities	$24.25M	$369.0K	$55.34M
YoY Change	96.95%	-98.03%
Cash From Investing Activities	$22.75M	-$67.00K	$54.03M
YoY Change	85.01%	-100.37%	-88.08%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net			-$144.0M
YoY Change			2868.86%
Debt Paid & Issued, Net	$473.4M		$0.00
YoY Change			-100.0%
Cash From Financing Activities	279.5M	-4.525M	451.5M
YoY Change	86.06%	-170.96%	-3537.91%
NET CHANGE
Cash From Operating Activities	-219.5M	-124.8M	-527.7M
Cash From Investing Activities	22.75M	-67.00K	54.03M
Cash From Financing Activities	279.5M	-4.525M	451.5M
Net Change In Cash	82.76M	-129.4M	-22.15M
YoY Change	354.12%	87.82%	-207.96%
FREE CASH FLOW
Cash From Operating Activities	-$219.5M	-$124.8M	-$527.7M
Capital Expenditures	$1.492M	$436.0K	$1.306M
Free Cash Flow	-$221.0M	-$125.3M	-$529.0M
YoY Change	53.14%	33.19%	24.68%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001743881
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue
CY2023Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2022Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2021Q4	us-gaap	Restricted Cash Noncurrent Asset Statement Of Financial Position Extensible List RestrictedCashNoncurrentAssetStatementOfFinancialPositionExtensibleList	http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent
CY2023Q4	us-gaap	Property Plant And Equipment Useful Life Description Of Term Extensible Enumeration PropertyPlantAndEquipmentUsefulLifeDescriptionOfTermExtensibleEnumeration	http://fasb.org/us-gaap/2023#UsefulLifeShorterOfTermOfLeaseOrAssetUtilityMember
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-38959
CY2023	dei	Entity Registrant Name EntityRegistrantName	BridgeBio Pharma, Inc.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	84-1850815
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	3160 Porter Drive
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 250
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Palo Alto
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	94304
CY2023	dei	City Area Code CityAreaCode	650
CY2023	dei	Local Phone Number LocalPhoneNumber	391-9740
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.001 per share
CY2023	dei	Trading Symbol TradingSymbol	BBIO
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	Yes
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	false
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	true
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	2075100000
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	175831536
CY2023	dei	Auditor Firm AuditorFirmId	34
CY2023	dei	Auditor Name AuditorName	Deloitte & Touche LLP
CY2023	dei	Auditor Location AuditorLocation	San Francisco, California
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	375935000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2023Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0
CY2022Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	51580000
CY2023Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	58949000
CY2022Q4	us-gaap	Equity Securities Fv Ni EquitySecuritiesFvNi	43653000
CY2023Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	1751000
CY2022Q4	us-gaap	Receivables Long Term Contracts Or Programs ReceivablesLongTermContractsOrPrograms	17079000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16653000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	37930000
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	24305000
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	21922000
CY2023Q4	us-gaap	Assets Current AssetsCurrent	477593000
CY2022Q4	us-gaap	Assets Current AssetsCurrent	548853000
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	11816000
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	14569000
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	8027000
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	10678000
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	26319000
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	28712000
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	22625000
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	20224000
CY2023Q4	us-gaap	Assets Assets	546380000
CY2022Q4	us-gaap	Assets Assets	623036000
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	10655000
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	11558000
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	57370000
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	31256000
CY2023Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	29765000
CY2022Q4	bbio	Accrued Research And Development Liabilities Current AccruedResearchAndDevelopmentLiabilitiesCurrent	39803000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4128000
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	3675000
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	6096000
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	8156000
CY2023Q4	bbio	Accrued Professional And Other Accrued Liabilities Current AccruedProfessionalAndOtherAccruedLiabilitiesCurrent	35830000
CY2022Q4	bbio	Accrued Professional And Other Accrued Liabilities Current AccruedProfessionalAndOtherAccruedLiabilitiesCurrent	26980000
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	143844000
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	121428000
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	446445000
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	430993000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8981000
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	12274000
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	9361000
CY2022Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	26643000
CY2023Q4	us-gaap	Liabilities Liabilities	1888915000
CY2022Q4	us-gaap	Liabilities Liabilities	1867960000
CY2023Q4	bbio	Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests	478000
CY2022Q4	bbio	Temporary Equity Carrying Amount Net Including Portion Attributable To Noncontrolling Interests TemporaryEquityCarryingAmountNetIncludingPortionAttributableToNoncontrollingInterests	-1589000
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	25000000
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	181274712
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	175082951
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	156817333
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	150625572
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	181000
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	157000
CY2023Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6191761
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	6191761
CY2023Q4	us-gaap	Treasury Stock Value TreasuryStockValue	275000000
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	275000000
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1481032000
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	938703000
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	31000
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-328000
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2560501000
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1918149000
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-1354257000
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-1254617000
CY2023Q4	us-gaap	Minority Interest MinorityInterest	11244000
CY2022Q4	us-gaap	Minority Interest MinorityInterest	11282000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1343013000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1243335000
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	546380000
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	623036000
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	9303000
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	77648000
CY2021	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	69716000
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	2446000
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	3434000
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	3114000
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	455711000
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	399462000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	451024000
CY2023	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	150590000
CY2022	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	143189000
CY2021	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	192210000
CY2023	us-gaap	Restructuring Charges RestructuringCharges	7926000
CY2022	us-gaap	Restructuring Charges RestructuringCharges	43765000
CY2021	us-gaap	Restructuring Charges RestructuringCharges	0
CY2023	us-gaap	Costs And Expenses CostsAndExpenses	616673000
CY2022	us-gaap	Costs And Expenses CostsAndExpenses	589850000
CY2021	us-gaap	Costs And Expenses CostsAndExpenses	646348000
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-607370000
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-512202000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-576632000
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	18038000
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	7542000
CY2021	us-gaap	Investment Income Interest InvestmentIncomeInterest	1133000
CY2023	us-gaap	Interest Expense InterestExpense	81289000
CY2022	us-gaap	Interest Expense InterestExpense	80438000
CY2021	us-gaap	Interest Expense InterestExpense	46778000
CY2023	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	0
CY2022	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	107946000
CY2021	bbio	Gain From Sale Of Priority Review Voucher Net GainFromSaleOfPriorityReviewVoucherNet	0
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	17370000
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-7500000
CY2021	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	35823000
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-45881000
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	27550000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-9822000
CY2023	us-gaap	Profit Loss ProfitLoss	-653251000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2023	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-10049000
CY2022	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3469000
CY2021	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-23915000
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-643202000
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-481183000
CY2021	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-562539000
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.95
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.95
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.26
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3.9
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3.9
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	162791511
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	162791511
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	147473076
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	147473076
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	144356619
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	144356619
CY2023	us-gaap	Profit Loss ProfitLoss	-653251000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	359000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-196000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2023	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-652892000
CY2022	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-484848000
CY2021	us-gaap	Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest	-586778000
CY2023	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-10049000
CY2022	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-3469000
CY2021	us-gaap	Comprehensive Income Net Of Tax Attributable To Noncontrolling Interest ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest	-23915000
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-642843000
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-481379000
CY2021	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-562863000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	106256000
CY2021Q4	bbio	Repurchase Of Noncontrolling Interests Transaction Costs RepurchaseOfNoncontrollingInterestsTransactionCosts	70734000
CY2021	us-gaap	Minority Interest Decrease From Redemptions MinorityInterestDecreaseFromRedemptions	-91997000
CY2021	bbio	Adjustments To Additional Paid In Capital Purchase Of Capped Calls AdjustmentsToAdditionalPaidInCapitalPurchaseOfCappedCalls	-61295000
CY2021	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	200000000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	89823000
CY2021	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	6240000
CY2021	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	3455000
CY2021	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-324000
CY2021	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-581129000
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-867002000
CY2022	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	94173000
CY2022	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	4815000
CY2022	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-2399000
CY2022	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-196000
CY2022	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-479241000
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1243335000
CY2023	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	98601000
CY2023	bbio	Issuance Repurchase Of Noncontrolling Interest IssuanceRepurchaseOfNoncontrollingInterest	-2006000
CY2023	us-gaap	Minority Interest Period Increase Decrease MinorityInterestPeriodIncreaseDecrease	-4851000
CY2023	us-gaap	Noncontrolling Interest Decrease From Deconsolidation NoncontrollingInterestDecreaseFromDeconsolidation	3951000
CY2023	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	359000
CY2023	bbio	Net Income Loss Excluding Redeemable Noncontrolling Interests Net Income Loss NetIncomeLossExcludingRedeemableNoncontrollingInterestsNetIncomeLoss	-648068000
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-1343013000
CY2023	us-gaap	Profit Loss ProfitLoss	-653251000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	108710000
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	91559000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	99505000
CY2023	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6494000
CY2022	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	6771000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	5843000
CY2023	bbio	Noncash Lease Expense NoncashLeaseExpense	4032000
CY2022	bbio	Noncash Lease Expense NoncashLeaseExpense	5172000
CY2021	bbio	Noncash Lease Expense NoncashLeaseExpense	5611000
CY2023	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	10207000
CY2022	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	13562000
CY2021	bbio	Accrual Of Payment In Kind Interest On Term Loan AccrualOfPaymentInKindInterestOnTermLoan	0
CY2023	bbio	Gain Loss On Deconsolidation Of Entities GainLossOnDeconsolidationOfEntities	-1241000
CY2022	bbio	Gain Loss On Deconsolidation Of Entities GainLossOnDeconsolidationOfEntities	0
CY2021	bbio	Gain Loss On Deconsolidation Of Entities GainLossOnDeconsolidationOfEntities	0
CY2023	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	18314000
CY2022	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	-8222000
CY2021	us-gaap	Equity Securities Fv Ni Gain Loss EquitySecuritiesFvNiGainLoss	29914000
CY2023	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	0
CY2022	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	4567000
CY2021	bbio	Fair Value Of Shares Issued Under License Agreements FairValueOfSharesIssuedUnderLicenseAgreements	0
CY2023	us-gaap	Accretion Expense AccretionExpense	8907000
CY2022	us-gaap	Accretion Expense AccretionExpense	8570000
CY2021	us-gaap	Accretion Expense AccretionExpense	5795000
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-984000
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1571000
CY2021	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1197000
CY2023	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2022	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-6261000
CY2021	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12720000
CY2021	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2023	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	0
CY2021	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	589892000
CY2022	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	110000000
CY2021	bbio	Gain From Sale Of Priority Review Voucher Excluding Transaction Costs GainFromSaleOfPriorityReviewVoucherExcludingTransactionCosts	0
CY2023	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	0
CY2022	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	12500000
CY2021	bbio	Gain From Recognition Of Receivable From Licensing And Collaboration Agreements GainFromRecognitionOfReceivableFromLicensingAndCollaborationAgreements	0
CY2023	bbio	Call Option Expense Income CallOptionExpenseIncome	0
CY2022	bbio	Call Option Expense Income CallOptionExpenseIncome	0
CY2021	bbio	Call Option Expense Income CallOptionExpenseIncome	-5550000
CY2023	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2022	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2021	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	-3337000
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-181000
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-604000
CY2021	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-7092000
CY2023	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	-15328000
CY2022	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	-15169000
CY2021	bbio	Increase Decrease Receivable From Licensing And Collaboration Agreements IncreaseDecreaseReceivableFromLicensingAndCollaborationAgreements	19749000
CY2023	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	2702000
CY2022	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7671000
CY2021	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	4262000
CY2023	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1546000
CY2022	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-10971000
CY2021	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	9816000
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2780000
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-349000
CY2021	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2833000
CY2023	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7802000
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-2362000
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	7378000
CY2023	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	-9855000
CY2022	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	-4309000
CY2021	bbio	Increase Decrease In Accrued Research And Development Liabilities IncreaseDecreaseInAccruedResearchAndDevelopmentLiabilities	11178000
CY2023	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-4829000
CY2022	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6245000
CY2021	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-6122000
CY2023	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-5438000
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	15262000
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	0
CY2023	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	3517000
CY2022	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-7729000
CY2021	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	14164000
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-527720000
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-419494000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-497934000
CY2023	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	29726000
CY2022	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	137493000
CY2023	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	82550000
CY2022	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	479688000
CY2021	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	380200000
CY2023	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2022	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	0
CY2021	bbio	Proceeds From Sale Of Marketable Securities ProceedsFromSaleOfMarketableSecurities	62691000
CY2023	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	107538000
CY2022	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	55562000
CY2021	us-gaap	Payments To Acquire Equity Securities Fv Ni PaymentsToAcquireEquitySecuritiesFvNi	53383000
CY2023	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	110556000
CY2022	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	52835000
CY2021	us-gaap	Proceeds From Sale Of Equity Securities Fv Ni ProceedsFromSaleOfEquitySecuritiesFvNi	34150000
CY2023	bbio	Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities	503000
CY2022	bbio	Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities	0
CY2021	bbio	Decrease In Cash And Cash Equivalents Resulting From Deconsolidation Of Entities DecreaseInCashAndCashEquivalentsResultingFromDeconsolidationOfEntities	0
CY2023	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	0
CY2022	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	0
CY2021	bbio	Proceeds From Consolidation Of Entities ProceedsFromConsolidationOfEntities	13654000
CY2023	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	0
CY2022	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	1500000
CY2021	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	35000000
CY2023	bbio	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	0
CY2022	bbio	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	110000000
CY2021	bbio	Proceeds From Sale Of Priority Review Voucher ProceedsFromSaleOfPriorityReviewVoucher	0
CY2023	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2022	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	10000000
CY2021	us-gaap	Proceeds From Sale Of Productive Assets ProceedsFromSaleOfProductiveAssets	0
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1306000
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	4821000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	13246000
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	54033000
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	453147000
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-200826000
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	240796000
CY2022	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2021	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	0
CY2023	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	144049000
CY2022	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2021	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0
CY2023	bbio	Proceeds From Issuance Of Common Stock Through At The Market Offering Net ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet	64965000
CY2022	bbio	Proceeds From Issuance Of Common Stock Through At The Market Offering Net ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet	4852000
CY2021	bbio	Proceeds From Issuance Of Common Stock Through At The Market Offering Net ProceedsFromIssuanceOfCommonStockThroughAtTheMarketOfferingNet	0
CY2023	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	747500000
CY2023	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Interest Paid Net InterestPaidNet	29774000
CY2023	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	100000
CY2022	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	47000
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	563000
CY2023	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0
CY2022	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	0
CY2022	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	0
CY2021	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	16064000
CY2023	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	0
CY2022	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	0
CY2021	bbio	Purchase Of Capped Calls PurchaseOfCappedCalls	61295000
CY2023	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2022	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	0
CY2021	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	200000000
CY2023	bbio	Financing Activity Transactions With Noncontrolling Interests FinancingActivityTransactionsWithNoncontrollingInterests	-801000
CY2022	bbio	Financing Activity Transactions With Noncontrolling Interests FinancingActivityTransactionsWithNoncontrollingInterests	0
CY2021	bbio	Financing Activity Transactions With Noncontrolling Interests FinancingActivityTransactionsWithNoncontrollingInterests	3500000
CY2023	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	0
CY2022	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	0
CY2021	bbio	Repurchase Of Noncontrolling Interest Including Direct Transaction Costs RepurchaseOfNoncontrollingInterestIncludingDirectTransactionCosts	85090000
CY2023	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2022	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	0
CY2021	us-gaap	Proceeds From Debt Net Of Issuance Costs ProceedsFromDebtNetOfIssuanceCosts	456296000
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	0
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	20486000
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	124119000
CY2023	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3398000
CY2022	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	2558000
CY2021	us-gaap	Proceeds From Stock Plans ProceedsFromStockPlans	3821000
CY2023	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	6880000
CY2022	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	1561000
CY2021	us-gaap	Payments Related To Tax Withholding For Share Based Compensation PaymentsRelatedToTaxWithholdingForShareBasedCompensation	4746000
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	6008000
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	666000
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	16643000
CY2023	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2022	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	837000
CY2021	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	0
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	451535000
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-13134000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	736446000
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-22152000
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	20519000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	37686000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	358679000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	394732000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2023	us-gaap	Interest Paid Net InterestPaidNet	61108000
CY2022	us-gaap	Interest Paid Net InterestPaidNet	54443000
CY2021	us-gaap	Payments For Tenant Improvements PaymentsForTenantImprovements	2449000
CY2023	bbio	Recognized Intangible Asset Recorded In Other Accrued And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedAndOtherLongTermLiabilities	0
CY2022	bbio	Recognized Intangible Asset Recorded In Other Accrued And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedAndOtherLongTermLiabilities	11000000
CY2021	bbio	Recognized Intangible Asset Recorded In Other Accrued And Other Long Term Liabilities RecognizedIntangibleAssetRecordedInOtherAccruedAndOtherLongTermLiabilities	12500000
CY2023	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-10534000
CY2022	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-3512000
CY2021	bbio	Noncash Or Part Noncash Investing Transfer From To Noncontrolling Interest NoncashOrPartNoncashInvestingTransferFromToNoncontrollingInterest	-2124000
CY2023	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	0
CY2022	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	0
CY2021	bbio	Noncash Or Part Noncash Contributions Made By Noncontrolling Interests NoncashOrPartNoncashContributionsMadeByNoncontrollingInterests	21600000
CY2023	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	0
CY2022	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	1763000
CY2021	bbio	Payment In Kind Interest Added To Principal Of Term Loan PaymentInKindInterestAddedToPrincipalOfTermLoan	0
CY2023	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2022	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	0
CY2021	us-gaap	Debt Issuance Costs Incurred During Noncash Or Partial Noncash Transaction DebtIssuanceCostsIncurredDuringNoncashOrPartialNoncashTransaction	1120000
CY2023	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	0
CY2022	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	0
CY2021	bbio	Net Non Cash Portion Of Repurchase Of Noncontrolling Interests NetNonCashPortionOfRepurchaseOfNoncontrollingInterests	38168000
CY2023	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	0
CY2022	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	0
CY2021	bbio	Direct Transaction Costs In Repurchase Of Noncontrolling Interest Recorded In Additional Paid In Capital Previously Classified In Prepaid Expenses And Other Current Assets DirectTransactionCostsInRepurchaseOfNoncontrollingInterestRecordedInAdditionalPaidInCapitalPreviouslyClassifiedInPrepaidExpensesAndOtherCurrentAssets	8749000
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	375935000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	16653000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	37930000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	177000
CY2023Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2144000
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2265000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	2416000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	394732000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	396365000
CY2023	us-gaap	Nature Of Operations NatureOfOperations	<div style="display:flex;margin-top:12pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:4.537%;display:inline-flex;justify-content:flex-start;">1.</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Organization and Description of Business </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">BridgeBio Pharma, Inc. (“BridgeBio” or the “Company”), is a commercial-stage biopharmaceutical company founded to discover, create, test and deliver transformative medicines to treat patients who suffer from genetic diseases and cancers with clear genetic drivers. BridgeBio</span><span style="color:#000000;white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;">’</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible.</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Since inception, BridgeBio has either created wholly-owned subsidiaries or has made investments in certain controlled entities, including partially-owned subsidiaries for which BridgeBio has a majority voting interest, and variable interest entities (“VIEs”) for which BridgeBio is the primary beneficiary (collectively, “we”, “our”, or “</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">us”). BridgeBio is headquartered in Palo Alto, California.</span></p>
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	393772000
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, and disclosure of contingent liabilities at the date of the consolidated financial statements, and the reported amounts of expenses during the reporting period. Significant estimates and assumptions made in the accompanying consolidated financial statements include, but are not limited to:</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accruals for research and development activities and contingent clinical, development, regulatory, and sales-based milestone payments in our in-licensing agreements and asset acquisitions, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">accruals for performance-based milestone compensation arrangements, </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">determining and allocating the transaction price to performance obligations for transactions accounted for under ASC 606,</span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;"> Revenue from Contracts with Customers </span><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">(“ASC 606”), </span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">the expected recoverability and estimated useful lives of our long-lived assets, and</span></div></div><div style="margin-left:4.528%;display:flex;margin-top:6pt;justify-content:flex-start;align-items:baseline;margin-bottom:0;min-width:4.537%;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:4.7521786492374725%;display:inline-flex;justify-content:flex-start;">•</span><div style="width:100%;display:inline;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">additional charges as a result of, or that are associated with, any restructuring initiative as well as impairment and related charges. </span></div></div><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">We base our estimates on historical experience and on various other assumptions that are believed to be reasonable. Actual results may differ from those estimates or assumptions.</span></p>
CY2023	bbio	Cash Cash Equivalents And Restricted Cash Maturity Period CashCashEquivalentsAndRestrictedCashMaturityPeriod	P90D
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	375935000
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	376689000
CY2023Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	16653000
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	37930000
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	177000
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2144000
CY2022Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2265000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	2416000
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	394732000
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	416884000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	396365000
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4100000
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	4100000
CY2021	us-gaap	Depreciation And Amortization DepreciationAndAmortization	3300000
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	17761000
CY2022Q4	us-gaap	Interest Payable Current InterestPayableCurrent	17500000
CY2023Q4	bbio	Milestone Liability MilestoneLiability	6000000
CY2022Q4	bbio	Milestone Liability MilestoneLiability	2500000
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	7412000
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	1790000
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4657000
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	5190000
CY2023Q4	bbio	Accrued Professional And Other Accrued Liabilities Current AccruedProfessionalAndOtherAccruedLiabilitiesCurrent	35830000
CY2022Q4	bbio	Accrued Professional And Other Accrued Liabilities Current AccruedProfessionalAndOtherAccruedLiabilitiesCurrent	26980000
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2023	bbio	Number Of Business Segments NumberOfBusinessSegments	1
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	0
CY2023Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2022Q4	bbio	Fair Value Assets Transfers Between Level One Level Two Or Level Three Amount FairValueAssetsTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2022Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2023Q4	bbio	Fair Value Liabilities Transfers Between Level One Level Two Or Level Three Amount FairValueLiabilitiesTransfersBetweenLevelOneLevelTwoOrLevelThreeAmount	0
CY2023	bbio	Gain From Conversion Of Equity Method Investment To Investment In Equity Securities GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities	0
CY2022	bbio	Gain From Conversion Of Equity Method Investment To Investment In Equity Securities GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities	0
CY2021	bbio	Gain From Conversion Of Equity Method Investment To Investment In Equity Securities GainFromConversionOfEquityMethodInvestmentToInvestmentInEquitySecurities	68538000
CY2023	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	8668000
CY2022	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	3731000
CY2021	us-gaap	Equity Securities Fv Ni Realized Gain Loss EquitySecuritiesFvNiRealizedGainLoss	2206000
CY2023	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	9646000
CY2022	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-11953000
CY2021	us-gaap	Equity Securities Fv Ni Unrealized Gain Loss EquitySecuritiesFvNiUnrealizedGainLoss	-40830000
CY2023	bbio	Net Gains Losses Included In Other Income Expense Net NetGainsLossesIncludedInOtherIncomeExpenseNet	18314000
CY2022	bbio	Net Gains Losses Included In Other Income Expense Net NetGainsLossesIncludedInOtherIncomeExpenseNet	-8222000
CY2021	bbio	Net Gains Losses Included In Other Income Expense Net NetGainsLossesIncludedInOtherIncomeExpenseNet	29914000
CY2021Q1	bbio	Leo Call Option Liability Current LEOCallOptionLiabilityCurrent	0
CY2021	bbio	Call Option Expense Income CallOptionExpenseIncome	-5600000
CY2023Q4	bbio	Estimated Fair Value Of Outstanding Term Loan EstimatedFairValueOfOutstandingTermLoan	389100000
CY2022Q4	bbio	Estimated Fair Value Of Outstanding Term Loan EstimatedFairValueOfOutstandingTermLoan	377200000
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	269566000
CY2023Q4	bbio	Cash Equivalents Unrealized Gains CashEquivalentsUnrealizedGains	31000
CY2023Q4	bbio	Cash Equivalents Unrealized Losses CashEquivalentsUnrealizedLosses	0
CY2023Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	269597000
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	362062000
CY2022Q4	bbio	Cash Equivalents Unrealized Gains CashEquivalentsUnrealizedGains	0
CY2022Q4	bbio	Cash Equivalents Unrealized Losses CashEquivalentsUnrealizedLosses	54000
CY2022Q4	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	362008000
CY2022Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	413916000
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0
CY2022Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	328000
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	413588000
CY2023	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2022	us-gaap	Debt Securities Available For Sale Realized Gain Loss DebtSecuritiesAvailableForSaleRealizedGainLoss	0
CY2023Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2022Q4	us-gaap	Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger	0
CY2022	bbio	Short Term Marketable Securities Contractual Maturities ShortTermMarketableSecuritiesContractualMaturities	P6M
CY2023	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-10500000
CY2022	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-3500000
CY2021	bbio	Adjustments Of Carrying Value Of Noncontrolling Interest Additional Paid In Capital AdjustmentsOfCarryingValueOfNoncontrollingInterestAdditionalPaidInCapital	-2100000
CY2023Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	1600000
CY2022Q4	us-gaap	Warrants Not Settleable In Cash Fair Value Disclosure WarrantsNotSettleableInCashFairValueDisclosure	600000
CY2023	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P11Y
CY2023Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32500000
CY2022	us-gaap	Acquired Finite Lived Intangible Assets Weighted Average Useful Life AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife	P12Y
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	32500000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	6181000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	3788000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	26319000
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	28712000
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2400000
CY2021	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2600000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths	2400000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Two FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearTwo	2400000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Three FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearThree	2400000
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Rolling Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingYearFour	2400000
CY2023Q4	bbio	Finite Lived Intangible Assets Amortization Expense Rolling After Year Four FiniteLivedIntangibleAssetsAmortizationExpenseRollingAfterYearFour	16700000
CY2022	us-gaap	Lease Cost LeaseCost	11757000
CY2021	us-gaap	Lease Cost LeaseCost	10256000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	1880000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	860000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	5611000
CY2023	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	420000
CY2022	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	443000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	402000
CY2023	us-gaap	Variable Lease Cost VariableLeaseCost	6844000
CY2022	us-gaap	Variable Lease Cost VariableLeaseCost	6142000
CY2021	us-gaap	Variable Lease Cost VariableLeaseCost	4243000
CY2023	us-gaap	Lease Cost LeaseCost	11296000
CY2023Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash PotentialMilestoneFixedMonetaryAmountSettlementInCash	9406000
CY2023Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash PotentialMilestoneAccruedAmountSettlementInCash	565000
CY2023Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Stock PotentialMilestoneFixedMonetaryAmountSettlementInStock	51550000
CY2023Q4	bbio	Potential Milestone Accrued Amount Settlement In Stock PotentialMilestoneAccruedAmountSettlementInStock	9092000
CY2023Q4	bbio	Potential Milestone Fixed Monetary Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneFixedMonetaryAmountSettlementInCashOrStockAtSoleDiscretion	129742000
CY2023Q4	bbio	Potential Milestone Accrued Amount Settlement In Cash Or Stock At Sole Discretion PotentialMilestoneAccruedAmountSettlementInCashOrStockAtSoleDiscretion	12572000
CY2023Q4	bbio	Potential Milestone Fixed Monetary Settlement Amount PotentialMilestoneFixedMonetarySettlementAmount	190698000
CY2023Q4	bbio	Potential Milestone Accrued Settlement Amount PotentialMilestoneAccruedSettlementAmount	22229000
CY2023Q4	bbio	Accrued Termination Charges AccruedTerminationCharges	0
CY2023	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	30569000
CY2023	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3662000
CY2023	us-gaap	Interest Expense Debt InterestExpenseDebt	34231000
CY2022	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	30569000
CY2022	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3568000
CY2022	us-gaap	Interest Expense Debt InterestExpenseDebt	34137000
CY2021	us-gaap	Interest Expense Debt Excluding Amortization InterestExpenseDebtExcludingAmortization	29307000
CY2021	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	3336000
CY2021	us-gaap	Interest Expense Debt InterestExpenseDebt	32643000
CY2023Q3	bbio	Children Intended For Treatement With Canavan Disease Maximum Age ChildrenIntendedForTreatementWithCanavanDiseaseMaximumAge	P5Y
CY2023	us-gaap	Operating Lease Cost OperatingLeaseCost	4032000
CY2022	us-gaap	Operating Lease Cost OperatingLeaseCost	5172000
CY2023	us-gaap	Operating Lease Payments OperatingLeasePayments	4829000
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	6245000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	6122000
CY2023	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	397000
CY2022	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	423000
CY2021	us-gaap	Finance Lease Interest Payment On Liability FinanceLeaseInterestPaymentOnLiability	272000
CY2023	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1179000
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	240000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	6380000
CY2023Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y8M12D
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P5Y3M18D
CY2023Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P2Y1M6D
CY2022Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P3Y1M6D
CY2023Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.06
CY2023Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.066
CY2022Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.066
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	4768000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	3949000
CY2023Q4	bbio	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	3418000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	14875000
CY2023Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1766000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13109000
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4128000
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8981000
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	13109000
CY2021	us-gaap	Operating Lease Impairment Loss OperatingLeaseImpairmentLoss	2600000
CY2019Q4	bbio	One Time Fees Receivable Noncurrent OneTimeFeesReceivableNoncurrent	10000000
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	115016000
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	93828000
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	105574000
CY2023	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	7900000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43800000
CY2023	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	0
CY2022	us-gaap	Impairment Of Long Lived Assets Held For Use ImpairmentOfLongLivedAssetsHeldForUse	12720000
CY2023	us-gaap	Severance Costs1 SeveranceCosts1	715000
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	10306000
CY2023	us-gaap	Business Exit Costs1 BusinessExitCosts1	7211000
CY2022	us-gaap	Business Exit Costs1 BusinessExitCosts1	20739000
CY2023	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	7926000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43765000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6826000
CY2021Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	0
CY2023	bbio	Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod	0
CY2022	bbio	Reclassification Of Final Payment Obligation Related To Manufacturing Agreement Recognized In Prior Period ReclassificationOfFinalPaymentObligationRelatedToManufacturingAgreementRecognizedInPriorPeriod	2185000
CY2023	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	7926000
CY2022	us-gaap	Restructuring Settlement And Impairment Provisions RestructuringSettlementAndImpairmentProvisions	43765000
CY2023	us-gaap	Payments For Restructuring PaymentsForRestructuring	14697000
CY2022	us-gaap	Payments For Restructuring PaymentsForRestructuring	25232000
CY2023	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	0
CY2022	us-gaap	Restructuring Reserve Settled Without Cash2 RestructuringReserveSettledWithoutCash2	13892000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	55000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6826000
CY2023Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	55000
CY2022Q4	us-gaap	Restructuring Reserve Current RestructuringReserveCurrent	6826000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-565840000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-485079000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-586478000
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-87411000
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	427000
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	24000
CY2023	us-gaap	Profit Loss ProfitLoss	-653251000
CY2022	us-gaap	Profit Loss ProfitLoss	-484652000
CY2021	us-gaap	Profit Loss ProfitLoss	-586454000
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2023	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2022	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2022	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	0
CY2021	us-gaap	Current Foreign Tax Expense Benefit CurrentForeignTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	0
CY2021	us-gaap	Deferred Foreign Income Tax Expense Benefit DeferredForeignIncomeTaxExpenseBenefit	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.203
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.217
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance	-0.256
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.023
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.032
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Tax Credits Research EffectiveIncomeTaxRateReconciliationTaxCreditsResearch	0.039
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.006
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	-0.018
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Share Based Compensation Excess Tax Benefit Percent EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent	0.012
CY2023	bbio	Effective Income Tax Rate Reconciliation Disallowed Executive Compensation EffectiveIncomeTaxRateReconciliationDisallowedExecutiveCompensation	-0.008
CY2022	bbio	Effective Income Tax Rate Reconciliation Disallowed Executive Compensation EffectiveIncomeTaxRateReconciliationDisallowedExecutiveCompensation	0
CY2021	bbio	Effective Income Tax Rate Reconciliation Disallowed Executive Compensation EffectiveIncomeTaxRateReconciliationDisallowedExecutiveCompensation	0
CY2023	bbio	Effective Income Tax Rate Reconciliation Deconsolidation EffectiveIncomeTaxRateReconciliationDeconsolidation	-0.014
CY2022	bbio	Effective Income Tax Rate Reconciliation Deconsolidation EffectiveIncomeTaxRateReconciliationDeconsolidation	0
CY2021	bbio	Effective Income Tax Rate Reconciliation Deconsolidation EffectiveIncomeTaxRateReconciliationDeconsolidation	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	-0.012
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Foreign Income Tax Rate Differential EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential	0
CY2023	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.002
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.007
CY2021	us-gaap	Effective Income Tax Rate Reconciliation Other Adjustments EffectiveIncomeTaxRateReconciliationOtherAdjustments	-0.005
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2021	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	358867000
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	325830000
CY2023Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	10024000
CY2022Q4	bbio	Deferred Tax Assets Amortization Of Assets DeferredTaxAssetsAmortizationOfAssets	9172000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	6453000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals	5261000
CY2023Q4	bbio	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	2130000
CY2022Q4	bbio	Deferred Tax Assets Deferred Revenue DeferredTaxAssetsDeferredRevenue	0
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	21340000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	16134000
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	97735000
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards DeferredTaxAssetsTaxCreditCarryforwards	86012000
CY2023Q4	bbio	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	3153000
CY2022Q4	bbio	Deferred Tax Assets Operating Lease Liabilities DeferredTaxAssetsOperatingLeaseLiabilities	3075000
CY2023Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2333000
CY2022Q4	us-gaap	Deferred Tax Assets Deferred Income DeferredTaxAssetsDeferredIncome	2391000
CY2023Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	144873000
CY2022Q4	us-gaap	Deferred Tax Assets In Process Research And Development DeferredTaxAssetsInProcessResearchAndDevelopment	77190000
CY2023Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	26596000
CY2022Q4	us-gaap	Deferred Tax Asset Interest Carryforward DeferredTaxAssetInterestCarryforward	13154000
CY2023Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	822000
CY2022Q4	us-gaap	Deferred Tax Assets Property Plant And Equipment DeferredTaxAssetsPropertyPlantAndEquipment	600000
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	4230000
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	268000
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	678556000
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	539087000
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	672084000
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	533929000
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	6472000
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	5158000
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	0
CY2023Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	1784000
CY2022Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	2001000
CY2023Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	4688000
CY2022Q4	us-gaap	Deferred Tax Liabilities Unrealized Gains On Trading Securities DeferredTaxLiabilitiesUnrealizedGainsOnTradingSecurities	3157000
CY2023Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	6472000
CY2022Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	5158000
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2017	bbio	Federal Net Operating Losses FederalNetOperatingLosses	28800000
CY2017	bbio	Federal Net Operating Losses Expiration Year FederalNetOperatingLossesExpirationYear	2036
CY2023	bbio	Federal Net Operating Losses FederalNetOperatingLosses	1500000000
CY2023	bbio	Percentage Of Taxable Income Limitation In Utilization Of Operating Loss Carry Forward PercentageOfTaxableIncomeLimitationInUtilizationOfOperatingLossCarryForward	0.80
CY2023	bbio	Operating Loss Carryforwards Expiration Year OperatingLossCarryforwardsExpirationYear	2036
CY2023	bbio	Research And Experimentation Expenditures Capital Account Amortized Period ResearchAndExperimentationExpendituresCapitalAccountAmortizedPeriod	P5Y
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	138200000
CY2022	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	110000000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	199500000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27013000
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	21254000
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	10000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	724000
CY2023	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	2504000
CY2022	us-gaap	Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions	0
CY2023	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	6337000
CY2022	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	5035000
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	30856000
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	27013000
CY2023	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Expense UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense	0
CY2022Q3	bbio	Percentage Of Corporate Alternative Minimum Tax Rate PercentageOfCorporateAlternativeMinimumTaxRate	0.15
CY2022Q3	bbio	Percentage Of Excise Tax Benefit On Corporate Stock Buy Back PercentageOfExciseTaxBenefitOnCorporateStockBuyBack	0.01
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	47261466
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	56406601
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	52252566

Files In Submission

Name	View Source	Status
0000950170-24-018811-index-headers.html	Edgar Link	pending
0000950170-24-018811-index.html	Edgar Link	pending
0000950170-24-018811.txt	Edgar Link	pending
0000950170-24-018811-xbrl.zip	Edgar Link	pending
bbio-20231231.htm	Edgar Link	pending
bbio-20231231.xsd	Edgar Link	pending
bbio-ex10_31.htm	Edgar Link	pending
bbio-ex10_39.htm	Edgar Link	pending
bbio-ex19.htm	Edgar Link	pending
bbio-ex21.htm	Edgar Link	pending
bbio-ex23_1.htm	Edgar Link	pending
bbio-ex31_1.htm	Edgar Link	pending
bbio-ex31_2.htm	Edgar Link	pending
bbio-ex32_1.htm	Edgar Link	pending
bbio-ex32_2.htm	Edgar Link	pending
bbio-ex97.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
img187994693_0.jpg	Edgar Link	pending
img187994693_1.jpg	Edgar Link	pending
img187994693_2.jpg	Edgar Link	pending
img187994693_3.jpg	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
bbio-20231231_htm.xml	Edgar Link	completed
img187994693_4.jpg	Edgar Link	pending
img187994693_5.jpg	Edgar Link	pending
img8472127_0.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R87.htm	Edgar Link	pending
R88.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$BBIO
BridgeBio Pharma, Inc. Stock $bbio

2024 Q1 Form 10-K Financial Statement

#000095017024018811 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO BridgeBio Pharma, Inc. Stock $bbio

2024 Q1 Form 10-K Financial Statement

#000095017024018811 Filed on February 22, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$BBIO
BridgeBio Pharma, Inc. Stock $bbio